person · Reporting owner
Shea Jacqueline Elizabeth
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director · Chief Executive Officer | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,021 |
Ending reported balance
After 2026-05-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-20 · Exercise / conversion · Acquired 28,296 · Balance 123,327 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Row 2 · 2026-05-20 · Tax withholding · Disposed 12,306 · Balance 111,021 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 56,592 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Exercise / conversion · Disposed 28,296 · Balance 56,592 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 100,240 |
Reported balance
After 2026-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-20 · Grant · Acquired 100,240 · Balance 100,240 F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 33,414 shares will vest on February 26, 2027; 33,413 shares will vest on February 26, 2028; and 33,413 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. |
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2036-05-20 | Direct | 123,760 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 123,760 · Balance 123,760 F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 41,254 shares will vest on February 26, 2027; 41,253 shares will vest on February 26, 2028; 41,253 shares will vest on February 26, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 41,254 shares will vest on February 26, 2027; 41,253 shares will vest on February 26, 2028; 41,253 shares will vest on February 26, 2029.
F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 33,414 shares will vest on February 26, 2027; 33,413 shares will vest on February 26, 2028; and 33,413 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 100,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001771498-26-000005 · wk-form4_1779393839.xml · derivative · entry 5 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,240 Underlying: Common Stock · 100,240 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 33,414 shares will vest on February 26, 2027; 33,413 shares will vest on February 26, 2028; and 33,413 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · date: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 33,414 shares will vest on February 26, 2027; 33,413 shares will vest on February 26, 2028; and 33,413 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 33,414 shares will vest on February 26, 2027; 33,413 shares will vest on February 26, 2028; and 33,413 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 123,760 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001771498-26-000005 · wk-form4_1779393839.xml · derivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,760 Underlying: Common Stock · 123,760 shares Expires 2036-05-20 F3 · date: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F4 · derivative.exercise_date: The vesting schedule for the options granted on May 20, 2026 was as follows: 41,254 shares will vest on February 26, 2027; 41,253 shares will vest on February 26, 2028; 41,253 shares will vest on February 26, 2029. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 28,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001771498-26-000005 · wk-form4_1779393839.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,592 Underlying: Common Stock · 28,296 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 12,306 | $1.23 | $15,136.38 |
DisclosureSEC source: 0001771498-26-000005 · wk-form4_1779393839.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,021 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:04 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 28,296 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001771498-26-000005 · wk-form4_1779393839.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units was as follows: 28,296 shares vested on May 20, 2026; 28,296 shares will vest on May 20, 2027; 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 17,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001771498-26-000004 · wk-form4_1779134885.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,744 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units was as follows: 17,745 shares vested on May 15, 2024; 17,744 shares vested on May 15, 2025; and 17,744 shares vested on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units was as follows: 17,745 shares vested on May 15, 2024; 17,744 shares vested on May 15, 2025; and 17,744 shares vested on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units was as follows: 17,745 shares vested on May 15, 2024; 17,744 shares vested on May 15, 2025; and 17,744 shares vested on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 7,717 | $1.30 | $10,032.10 |
DisclosureSEC source: 0001771498-26-000004 · wk-form4_1779134885.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,031 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 15, 2026 Filed May 18, 2026 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 17,744 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001771498-26-000004 · wk-form4_1779134885.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units was as follows: 17,745 shares vested on May 15, 2024; 17,744 shares vested on May 15, 2025; and 17,744 shares vested on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:55 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 78,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001771498-26-000003 · wk-form4_1772747707.xml · derivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,760 Underlying: Common Stock · 78,760 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 78,760 restricted stock units granted on March 4, 2026 was as follows: 26,254 shares will vest on February 26, 2027; 26,253 shares will vest on February 26, 2028; and 26,253 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 78,760 restricted stock units granted on March 4, 2026 was as follows: 26,254 shares will vest on February 26, 2027; 26,253 shares will vest on February 26, 2028; and 26,253 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 78,760 restricted stock units granted on March 4, 2026 was as follows: 26,254 shares will vest on February 26, 2027; 26,253 shares will vest on February 26, 2028; and 26,253 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:55 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 97,240 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001771498-26-000003 · wk-form4_1772747707.xml · derivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,240 Underlying: Common Stock · 97,240 shares Expires 2036-02-26 F1 · derivative.exercise_date: The vesting schedule for the 97,240 options granted on March 4, 2026 was as follows: 32,414 shares will vest on February 26, 2027; 32,413 shares will vest on February 26, 2028; 32,413 shares will vest on February 26, 2029. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 28,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001771498-26-000002 · wk-form4_1772228868.xml · derivative · entry 6 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,800 Underlying: Common Stock · 28,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,201 restricted stock units granted on February 27, 2025 was as follows: 28,401 shares vested on February 26, 2026; 28,400 shares will vest on February 26, 2027; 28,400 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,201 restricted stock units granted on February 27, 2025 was as follows: 28,401 shares vested on February 26, 2026; 28,400 shares will vest on February 26, 2027; 28,400 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,201 restricted stock units granted on February 27, 2025 was as follows: 28,401 shares vested on February 26, 2026; 28,400 shares will vest on February 26, 2027; 28,400 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 18,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001771498-26-000002 · wk-form4_1772228868.xml · derivative · entry 5 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,631 Underlying: Common Stock · 18,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 was as follows: 18,632 shares vested on February 26, 2025; 18,632 shares vested on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 was as follows: 18,632 shares vested on February 26, 2025; 18,632 shares vested on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 was as follows: 18,632 shares vested on February 26, 2025; 18,632 shares vested on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 13,657 | $1.79 | $24,446.03 |
DisclosureSEC source: 0001771498-26-000002 · wk-form4_1772228868.xml · nonDerivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,004 F4 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 28,401 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001771498-26-000002 · wk-form4_1772228868.xml · nonDerivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,201 restricted stock units granted on February 27, 2025 was as follows: 28,401 shares vested on February 26, 2026; 28,400 shares will vest on February 26, 2027; 28,400 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 8,057 | $1.79 | $14,422.03 |
DisclosureSEC source: 0001771498-26-000002 · wk-form4_1772228868.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,260 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:47 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 18,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001771498-26-000002 · wk-form4_1772228868.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 was as follows: 18,632 shares vested on February 26, 2025; 18,632 shares vested on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 20, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 105,262 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001055726-25-000042 · wk-form4_1747861132.xml · derivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,262 Underlying: Common Stock · 105,262 shares Expires 2035-05-20 F2 · derivative.exercise_date: The vesting schedule for the 105,262 options is as follows: 52,631 shares will vest on May 20, 2027 and 52,631 shares will vest on May 20, 2028. Read SEC document |
| May 20, 2025 Filed May 21, 2025 20:58 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 84,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000042 · wk-form4_1747861132.xml · derivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,888 Underlying: Common Stock · 84,888 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units is as follows: 28,296 shares will vest on May 20, 2026; 28,296 shares will vest on May 20, 2027; and 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units is as follows: 28,296 shares will vest on May 20, 2026; 28,296 shares will vest on May 20, 2027; and 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 84,888 restricted stock units is as follows: 28,296 shares will vest on May 20, 2026; 28,296 shares will vest on May 20, 2027; and 28,296 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 17,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000030 · wk-form4_1747426107.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,744 Underlying: Common Stock · 17,744 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares vested on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares vested on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares vested on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 7,717 | $1.95 | $15,048.15 |
DisclosureSEC source: 0001055726-25-000030 · wk-form4_1747426107.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,685 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 15, 2025 Filed May 16, 2025 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 17,744 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000030 · wk-form4_1747426107.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares vested on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 10, 2025 Filed May 12, 2025 20:39 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000020 · wk-form4_1747082363.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units was as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares vested on May 10, 2025. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units was as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares vested on May 10, 2025. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units was as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares vested on May 10, 2025. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 10, 2025 Filed May 12, 2025 20:39 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 2,392 | $1.80 | $4,305.60 |
DisclosureSEC source: 0001055726-25-000020 · wk-form4_1747082363.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,658 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 10, 2025 Filed May 12, 2025 20:39 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000020 · wk-form4_1747082363.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units was as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares vested on May 10, 2025. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 85,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000003 · wk-form4_1740783933.xml · derivative · entry 8 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,201 Underlying: Common Stock · 85,201 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,201 restricted stock units granted on February 27, 2025 is as follows: 28,401 shares will vest on February 26, 2026; 28,400 shares will vest on February 26, 2027; and 28,400 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,201 restricted stock units granted on February 27, 2025 is as follows: 28,401 shares will vest on February 26, 2026; 28,400 shares will vest on February 26, 2027; and 28,400 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 85,201 restricted stock units granted on February 27, 2025 is as follows: 28,401 shares will vest on February 26, 2026; 28,400 shares will vest on February 26, 2027; and 28,400 shares will vest on February 26, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 105,649 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001055726-25-000003 · wk-form4_1740783933.xml · derivative · entry 7 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,649 Underlying: Common Stock · 105,649 shares Expires 2035-02-27 F5 · derivative.exercise_date: The vesting schedule for the 105,649 options is as follows: 52,825 shares vested on February 27, 2025 and 52,824 shares will vest on February 26, 2026. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 18,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000003 · wk-form4_1740783933.xml · derivative · entry 6 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,263 Underlying: Common Stock · 18,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 is as follows: 18,632 shares vested on February 26, 2025; 18,632 shares will vest on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 is as follows: 18,632 shares vested on February 26, 2025; 18,632 shares will vest on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 is as follows: 18,632 shares vested on February 26, 2025; 18,632 shares will vest on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 5,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-25-000003 · wk-form4_1740783933.xml · derivative · entry 5 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,852 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units granted on February 26, 2022 was as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units granted on February 26, 2022 was as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units granted on February 26, 2022 was as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 9,088 | $1.98 | $17,994.24 |
DisclosureSEC source: 0001055726-25-000003 · wk-form4_1740783933.xml · nonDerivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,550 F4 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (3) herein. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 18,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000003 · wk-form4_1740783933.xml · nonDerivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units granted on February 28, 2024 is as follows: 18,632 shares vested on February 26, 2025; 18,632 shares will vest on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 2,493 | $1.98 | $4,936.14 |
DisclosureSEC source: 0001055726-25-000003 · wk-form4_1740783933.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,006 F2 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 23:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 5,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-25-000003 · wk-form4_1740783933.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units granted on February 26, 2022 was as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:59 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 17,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000024 · wk-form4_1715893155.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,488 Underlying: Common Stock · 17,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares will vest on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares will vest on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares will vest on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:59 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 7,718 | $13.07 | $100,874.26 |
DisclosureSEC source: 0001055726-24-000024 · wk-form4_1715893155.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,647 F3 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:59 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 17,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000024 · wk-form4_1715893155.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 53,233 restricted stock units is as follows: 17,745 shares vested on May 15, 2024; 17,744 shares will vest on May 15, 2025; and 17,744 shares will vest on May 15, 2026. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 10, 2024 Filed May 13, 2024 20:57 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000022 · wk-form4_1715633831.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units is as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units is as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units is as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 10, 2024 Filed May 13, 2024 20:57 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 2,392 | $10.65 | $25,474.80 |
DisclosureSEC source: 0001055726-24-000022 · wk-form4_1715633831.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,620 F3 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| May 10, 2024 Filed May 13, 2024 20:57 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000022 · wk-form4_1715633831.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units is as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 55,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000005 · wk-form4_1709158138.xml · derivative · entry 8 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,895 Underlying: Common Stock · 55,895 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units is as follows: 18,632 shares will vest on February 26, 2025; 18,632 shares will vest on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F7 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units is as follows: 18,632 shares will vest on February 26, 2025; 18,632 shares will vest on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F7 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 55,895 restricted stock units is as follows: 18,632 shares will vest on February 26, 2025; 18,632 shares will vest on February 26, 2026; and 18,631 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 69,733 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001055726-24-000005 · wk-form4_1709158138.xml · derivative · entry 7 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,733 Underlying: Common Stock · 69,733 shares Expires 2034-02-28 F6 · derivative.exercise_date: The vesting schedule for the 69,733 options is as follows: 17,434 shares vested on February 28, 2024; 17,433 shares will vest on February 28, 2025; 17,433 shares will vest on February 28, 2026; and 17,433 shares will vest on February 28, 2027. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 5,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000005 · wk-form4_1709158138.xml · derivative · entry 6 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,852 Underlying: Common Stock · 5,853 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units is as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units is as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units is as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-24-000005 · wk-form4_1709158138.xml · derivative · entry 5 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 2,856 | $8.16 | $23,304.96 |
DisclosureSEC source: 0001055726-24-000005 · wk-form4_1709158138.xml · nonDerivative · entry 4 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,512 F5 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (4) herein. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 5,853 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000005 · wk-form4_1709158138.xml · nonDerivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 17,557 restricted stock units is as follows: 5,852 shares vested on February 26, 2023; 5,853 shares vested on February 26, 2024; and 5,852 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 872 | $8.16 | $7,115.52 |
DisclosureSEC source: 0001055726-24-000005 · wk-form4_1709158138.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,515 F3 · shares: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 22:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 1,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-24-000005 · wk-form4_1709158138.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both. F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 638,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000040 · wk-form4_1684354107.xml · derivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638,800 Underlying: Common Stock · 638,800 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 638,800 restricted stock units is as follows: 212,934 shares will vest on May 15, 2024; 212,933 shares will vest on May 15, 2025; and 212,933 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 638,800 restricted stock units is as follows: 212,934 shares will vest on May 15, 2024; 212,933 shares will vest on May 15, 2025; and 212,933 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 638,800 restricted stock units is as follows: 212,934 shares will vest on May 15, 2024; 212,933 shares will vest on May 15, 2025; and 212,933 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-23-000032 · wk-form4_1683922339.xml · derivative · entry 3 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,000 Underlying: Common Stock · 66,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 198,000 restricted stock units is as follows: 66,000 shares vested on May 10, 2023; 66,000 shares will vest on May 10, 2024; 66,000 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 198,000 restricted stock units is as follows: 66,000 shares vested on May 10, 2023; 66,000 shares will vest on May 10, 2024; 66,000 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 198,000 restricted stock units is as follows: 66,000 shares vested on May 10, 2023; 66,000 shares will vest on May 10, 2024; 66,000 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 28,704 | $0.81 | $23,250.24 |
DisclosureSEC source: 0001055726-23-000032 · wk-form4_1683922339.xml · nonDerivative · entry 2 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,113 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:12 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 66,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000032 · wk-form4_1683922339.xml · nonDerivative · entry 1 Shea Jacqueline Elizabeth · CIK 0001771498 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 198,000 restricted stock units is as follows: 66,000 shares vested on May 10, 2023; 66,000 shares will vest on May 10, 2024; 66,000 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.